Management of hyperglycaemia with non-insulin drugs in adult patients with type 2 diabetes

被引：7

作者：

Alvarez-Guisasola, Fernando ^{[1
]}

Orozco-Beltran, Domingo ^{[2
]}

Cebrian-Cuenca, Ana M. ^{[3
]}

Ruiz Quintero, Manuel Antonio ^{[4
]}

Angullo Martinez, Escarlata ^{[5
]}

Avila Lachica, Luis ^{[6
]}

Ortega Milian, Carlos ^{[7
]}

Caride Miana, Elena ^{[8
]}

Navarro-Perez, Jorge ^{[9
]}

Sagredo Perez, Julio ^{[10
]}

Barrot de la Puente, Joan ^{[11
]}

Cos Claramunt, Francesc Xavier ^{[12
]}

机构：

[1] Ctr Salud Ribera Orbigo, Med Familiar & Comunitaria, Leon, Spain

[2] Ctr Salud Cabo Huertas, Dept San Juan Alicante, Unidad Invest, Med Familiar & Comunitaria, Alicante, Spain

[3] Ctr Salud Cartagena Casco, Med Familiar & Comunitaria, Murcia, Spain

[4] Ctr Salud Agost, Med Familiar & Comunitaria, Alicante, Spain

[5] Ctr Salud Escola Graduada, Med Familiar & Comunitaria, Palma De Mallorca, Spain

[6] UGC Velez Norte, Med Familiar & Comunitaria, Consultorio Almachar, Malaga, Spain

[7] Ctr Salud Pozoblanco, Med Familiar & Comunitaria, Cordoba, Spain

[8] Ctr Salud Foietes, Med Familiar & Comunitaria, Alicante, Spain

[9] Univ Valencia, Hosp Clin Univ Valencia, Med Familiar & Comunitaria, INCLIVA,CIBERESP, Valencia, Spain

[10] Ctr Salud Parque Europa, Med Familiar & Comunitaria, Madrid, Spain

[11] Ctr Salud Jordi Nadal, Med Familiar & Comunitaria, Pinto, Girona, Spain

[12] Univ Autonoma Barcelona, Med Familiar & Comunitaria, Barcelona, Spain

来源：

ATENCION PRIMARIA | 2019年 / 51卷 / 07期

关键词：

Type; 2; diabetes; Hyperglycemia; Antidiabetic drugs; PIOGLITAZONE CLINICAL-TRIAL; MACROVASCULAR EVENTS; MELLITUS; COMBINATION; SITAGLIPTIN; PREVENTION; OUTCOMES; RISK;

D O I：

10.1016/j.aprim.2019.05.014

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Treatment of diabetes mellitus type 2 (DM2) includes healthy eating and exercise (150 minutes/week) as basic pillars. For pharmacological treatment, metformin is the initial drug except contraindication or intolerance; in case of poor control, 8 therapeutic families are available (6 oral and 2 injectable) as possible combinations. An algorithm and some recommendations for the treatment of DM2 are presented. In secondary cardiovascular prevention, it is recommended to associate an inhibitor of the sodium-glucose cotransporter type 2 (iSGLT2) or a glucagon-like peptide-1 receptor agonist (arGLP1) in patients with obesity. In primary prevention if the patient is obese or overweight metformin should be combined with iSGLT2, arGLP1, or inhibitors of type 4 dipeptidylpeptidase (iDPP4). If the patient does not present obesity, iDPP4, iSGLT2 or gliclazide, sulfonylurea, recommended due to its lower tendency to hypoglycaemia, may be used. (C) 2019 Published by Elsevier Espana, S.L.U.

引用

页码：442 / 451

页数：10

共 41 条

[1]

[Anonymous], 2015, FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood

[2]

[Anonymous], 2018, Diabetes Care, V42, pS61, DOI [DOI 10.2337/DC19-S006, 10.2337/dc19-S006]

[3]

Arnett DK, 2019, CIRCULATION, V140, pE596, DOI [10.1161/CIR.0000000000000677, 10.1016/j.jacc.2019.03.010, 10.1161/CIR.0000000000000678, 10.1016/j.jacc.2019.03.009]

[4] Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study [J].

Aroda, Vanita R. ;

Edelstein, Sharon L. ;

Goldberg, Ronald B. ;

Knowler, William C. ;

Marcovina, Santica M. ;

Orchard, Trevor J. ;

Bray, George A. ;

Schade, David S. ;

Temprosa, Marinella G. ;

White, Neil H. ;

Crandall, Jill P. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (04) :1754-1761

[5]

Artola S, 2017, DIABETES PRACTICA SU, V8, P1, DOI [10.26322/2013.7923.1505400426.03, DOI 10.26322/2013.7923.1505400426.03]

[6]

Brotons Cuixart Carlos, 2018, Aten Primaria, V50 Suppl 1, P4, DOI 10.1016/S0212-6567(18)30360-3

[7] Clinical Assessment of Individualized Glycemic Goals in Patients With Type 2 Diabetes: Formulation of an Algorithm Based on a Survey Among Leading Worldwide Diabetologists [J].

Cahn, Avivit ;

Raz, Itamar ;

Kleinman, Yosef ;

Balicer, Ran ;

Hoshen, Moshe ;

Lieberman, Nicky ;

Brenig, Naomi ;

Del Prato, Stefano ;

Cefalu, William T. .

DIABETES CARE, 2015, 38 (12) :2293-2300

[8]

Canadian Agency for Drugs and Technologies in Health, CAN NEW DRUGS TYP 2

[9] Improving Care and Promoting Health in Populations: Standards of Medical Care in Diabetes-2019 [J].

Cefalu, William T. ;

Berg, Erika Gebel ;

Saraco, Mindy ;

Petersen, Matthew P. ;

Uelmen, Sacha ;

Robinson, Shamera .

DIABETES CARE, 2019, 42 :S7-S12

[10] Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents [J].

Chan, Siew Pheng ;

Colagiuri, Stephen .

DIABETES RESEARCH AND CLINICAL PRACTICE, 2015, 110 (01) :75-81

← 1 2 3 4 5 →